What neonatal risks are associated with Zypadhera exposure during the third trimester of pregnancy?

Third-trimester exposure to Zypadhera (olanzapine) puts newborns at risk of extrapyramidal and/or withdrawal symptoms of varying severity and duration after delivery, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress or feeding disorder, so newborns should be monitored carefully.